Reaction
Malignant Ascites reporting signals
As of the last recalculation, Malignant Ascites appears in 757 FAERS reports alongside 31 co-occurring drug terms. The strongest observed disproportionality signal is GRANISETRON HYDROCHLORIDE (PRR 32.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Granisetron Hydrochloride | 12 | 32.1 | 32.1 |
| Leucovorin Calcium | 20 | 29.5 | 29.6 |
| Irinotecan Hydrochloride | 13 | 28.3 | 28.3 |
| Trifluridine And Tipiracil | 10 | 26.0 | 26.0 |
| Granisetron | 9 | 23.9 | 23.9 |
| Fulvestrant | 27 | 23.3 | 23.3 |
| Sitagliptin And Metformin Hydrochloride | 17 | 22.1 | 22.2 |
| Prochlorperazine Maleate | 7 | 21.1 | 21.1 |
| Goserelin | 10 | 20.7 | 20.8 |
| Erlotinib Hydrochloride | 9 | 20.0 | 20.0 |
| Regorafenib | 8 | 19.1 | 19.2 |
| Dexamethasone Sodium Phosphate | 7 | 19.1 | 19.1 |
| Olaparib | 14 | 18.7 | 18.7 |
| Bevacizumab | 75 | 18.4 | 18.4 |
| Fluorouracil Cream, 0.5% | 47 | 18.0 | 18.0 |
| Gemcitabine Hydrochloride | 33 | 17.8 | 17.8 |
| Fluorouracil | 47 | 17.7 | 17.8 |
| Gemcitabine | 24 | 17.3 | 17.3 |
| Niraparib | 13 | 16.4 | 16.4 |
| Capecitabine | 49 | 15.7 | 15.7 |
| Oxaliplatin | 40 | 15.6 | 15.6 |
| Panitumumab | 8 | 14.2 | 14.2 |
| Exenatide | 26 | 14.0 | 14.0 |
| Lapatinib | 7 | 12.5 | 12.5 |
| Paclitaxel (Aibumin-Bound) | 35 | 12.2 | 12.2 |
| Paclitaxel | 41 | 12.0 | 12.0 |
| Pembrolizumab | 43 | 11.9 | 11.9 |
| Erlotinib | 4 | 11.4 | 11.4 |
| Fam-Trastuzumab Deruxtecan-Nxki | 4 | 11.0 | 11.0 |
| Durvalumab | 7 | 9.5 | 9.5 |
| Rucaparib | 3 | 9.4 | 9.4 |